New hope for leukemia patients out of treatment options
NCT ID NCT06514534
Summary
This study is testing whether the drug asciminib can help control chronic myeloid leukemia in patients with a specific genetic mutation called T315I. The trial focuses on people who have already tried other treatments and either didn't respond well or couldn't tolerate them. Researchers will monitor how well the drug works and check for side effects in about 20 participants over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGLyon, 69373, France
-
Novartis Investigative Site
RECRUITINGNantes, 44093, France
Conditions
Explore the condition pages connected to this study.